C
코아스템켐온
166480KOSDAQ44.5 / 100
Reference Date: 2026-09-08
Financial Score12.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 4.5% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
CoaStemKemOn focuses on developing and selling stem cell therapies, with its product 'NeuroNata-Al' for Lou Gehrig's disease commercialized since 2015. The company merged with KemOn, a top non-clinical CRO firm in South Korea, in 2022 to enhance R&D capabilities, and approximately 98% of its revenue comes from non-clinical research services.
Number of Employees
321people
Average Salary
48.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
2.09Industry Average 1.201.0Point
1.7x industry avg (risky)
ROE
-51.72Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
36.21Industry Average 100.006.5Point
Half of industry avg (excellent)
Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼22.2% (2-year basis)
Operating Profit Growth Rate
0.5 / 3
Avg ▼4.1% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -63.1% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position3.0Point
52w lower range (30%)
Current 2,185Won52-week high 4,80052-week low 1,060
1-month return4.0Point
1m +4.55% (slight rise)
Volume trend3.0Point
Volume flat
Detailed Disclosure
4 totalPositive 0Neutral 4Negative 0
- Neutral교환청구권행사 (제2회, 3회, 4회차)2026-09-04
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-03
- Neutral주식등의대량보유상황보고서(일반)2026-09-03
- Neutral반기보고서 (2026.06)2026-08-14